US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 17:16:24 Source:businessViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Analysis: Larson enters conversation with Verstappen as best drivers in the world
Next:'The Apprentice,' about a young Donald Trump, premieres in Cannes
You may also like
- Supreme Court declines to hear challenge to Maryland ban on rifles known as assault weapons
- Report: Chinese swimmers were allowed to compete at Tokyo Olympics despite positive doping tests
- Ryan Reynolds says Michael J. Fox helped his late father James 'feel less alone' in his 20
- Tori Spelling admits she once put on her son's diaper and PEED in it while stuck in traffic
- Election 2024: Biden and Trump bypassed the Commission on Presidential Debates
- Rachel Brosnahan and Melissa McCarthy suit up for opening night of Broadway musical Suffs in NYC
- US says a UN agency has agreed to help in distribution of aid to Gaza via sea route
- Dozens of Palestinians killed, injured in Israeli attack in Gaza City
- Iran helicopter crash that killed President Raisi could reverberate across the Middle East